Tyra Biosciences targets resistance in oncology with purpose built drugs for the benefit of patients.
TYRA
13.76 as of 6/1/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 3/31/2021 | Series B | $106.3MM raised | $XXX.XX | $XXX.XX |
| 1/10/2020 | Series A | $51.34MM raised | $XXX.XX | $XXX.XX |
